Literature DB >> 11250151

Control of progenitor cell number by mitogen supply and demand.

P van Heyningen1, A R Calver, W D Richardson.   

Abstract

BACKGROUND: Much is known about how cell proliferation is controlled at the single cell level, but much less about the control of cell numbers in developing populations. Cell number might be determined by an intracellular division limiter or, alternatively, by the availability of mitogens or other factors outside the cell. We investigated the relative importance of intracellular and extracellular controls for one well-defined population of neural precursor cells, namely the glial progenitors that give rise to oligodendrocytes in the mouse spinal cord.
RESULTS: We found by cumulative BrdU labeling in vivo that the progenitor cell division cycle slows down markedly as their numbers increase during embryogenesis. When cultured in saturating PDGF, the main mitogen for these cells, their cell cycle accelerated and was independent of their prior rate of division in vivo. This shows that mitogens are limiting in vivo, and suggests that division normally slows down because the PDGF concentration declines. In PDGF-transgenic mice, cell number was proportional to the PDGF supply and apparently unsaturable; at ten times the normal rate of supply, cell number was still increasing but the animals were no longer viable.
CONCLUSIONS: Progenitor cell proliferation in the embryo is limited by environmental factors, not a cell-intrinsic mechanism. The linear relationship between PDGF supply and final cell number strongly suggests that cells deplete the mitogenic activity in their environment at a rate proportional to the total number of cells. The cells might simply consume the available PDGF or they might secrete autocrine inhibitors, or both.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250151     DOI: 10.1016/s0960-9822(01)00075-6

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  58 in total

1.  The oligodendrocyte precursor mitogen PDGF stimulates proliferation by activation of alpha(v)beta3 integrins.

Authors:  Wia Baron; Sanford J Shattil; Charles ffrench-Constant
Journal:  EMBO J       Date:  2002-04-15       Impact factor: 11.598

Review 2.  PDGF function in diverse neural crest cell populations.

Authors:  Christopher L Smith; Michelle D Tallquist
Journal:  Cell Adh Migr       Date:  2010 Oct-Dec       Impact factor: 3.405

Review 3.  Oligodendrocyte Development and Plasticity.

Authors:  Dwight E Bergles; William D Richardson
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-08-20       Impact factor: 10.005

4.  Glial progenitor cell recruitment drives aggressive glioma growth: mathematical and experimental modelling.

Authors:  Susan Christine Massey; Marcela C Assanah; Kim A Lopez; Peter Canoll; Kristin R Swanson
Journal:  J R Soc Interface       Date:  2012-02-07       Impact factor: 4.118

5.  The NG2 proteoglycan promotes oligodendrocyte progenitor proliferation and developmental myelination.

Authors:  K Kucharova; W B Stallcup
Journal:  Neuroscience       Date:  2009-12-16       Impact factor: 3.590

Review 6.  The interface between glial progenitors and gliomas.

Authors:  Peter Canoll; James E Goldman
Journal:  Acta Neuropathol       Date:  2008-09-11       Impact factor: 17.088

Review 7.  Role of platelet-derived growth factors in physiology and medicine.

Authors:  Johanna Andrae; Radiosa Gallini; Christer Betsholtz
Journal:  Genes Dev       Date:  2008-05-15       Impact factor: 11.361

8.  Differing intrinsic biological properties between forebrain and spinal oligodendroglial lineage cells.

Authors:  Makoto Horiuchi; Yoko Suzuki-Horiuchi; Tasuku Akiyama; Aki Itoh; David Pleasure; Earl Carstens; Takayuki Itoh
Journal:  J Neurochem       Date:  2017-06-09       Impact factor: 5.372

9.  Platelet-derived growth factor promotes repair of chronically demyelinated white matter.

Authors:  Adam C Vana; Nicole C Flint; Norah E Harwood; Tuan Q Le; Marcus Fruttiger; Regina C Armstrong
Journal:  J Neuropathol Exp Neurol       Date:  2007-11       Impact factor: 3.685

10.  Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

Authors:  Eric Raymond; Alba A Brandes; Christian Dittrich; Pierre Fumoleau; Bruno Coudert; Paul M J Clement; Marc Frenay; Roy Rampling; Roger Stupp; Johan M Kros; Michael C Heinrich; Thierry Gorlia; Denis Lacombe; Martin J van den Bent
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.